Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Chasity Sullivan

Family Medicine Fort Smith, AR Nurse Practitioner

NPI 1851088561 CMS profile 11461136

10929 Old Highway 71, Fort Smith, AR 72916

Open in the dashboard

General payments

$7,744

368 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chasity Sullivan of Fort Smith, AR is reported in the CMS Open Payments database as having received $7,744 across 368 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $831 36
2024 General $4,522 207
2023 General $2,391 125

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chasity Sullivan
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Chasity Sullivan were reported at $831. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Chasity Sullivan Family Medicine median Middle half National median
2019 $0 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $0 $137 $35–$551 $132
2022 $0 $137 $37–$512 $149
2023 $2,391 $149 $42–$545 $160
2024 $4,522 $156 $44–$560 $164
2025 $831 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. UCB, Inc. $771 31 payments
  2. EMD Serono, Inc. $757 27 payments
  3. Novartis Pharmaceuticals Corporation $683 36 payments
  4. AbbVie, Inc. $617 54 payments
  5. SK Life Science, Inc. $584 22 payments
  6. Pfizer Inc. $540 37 payments
  7. US WorldMeds, LLC $498 11 payments
  8. Kyowa Kirin, Inc. $437 14 payments
  9. Neurocrine Biosciences, Inc. $355 19 payments
  10. Lundbeck LLC $306 14 payments
  11. Other $2,197 103 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $7,744 368 payments
Products named General payments · program years 2023–2025
  1. KESIMPTA $683 36 payments
  2. Briviact $522 24 payments
  3. NOURIANZ $437 14 payments
  4. NURTEC ODT $373 28 payments
  5. ZAVZPRET $362 27 payments
  6. INGREZZA $355 19 payments
  7. QULIPTA $353 39 payments
  8. Gocovri $350 3 payments
  9. VYEPTI $306 14 payments
  10. MAVENCLAD $290 12 payments
  11. Other $4,004 191 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

2,324

Median for Family Practice: 1,826

Drug cost

$851,406

Median for Family Practice: $120,094

Branded share of claims

20.8%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 23 $464,916
Ingrezza Valbenazine Tosylate Brand 22 $179,954
Emgality Pen Galcanezumab-Gnlm Brand 44 $43,445
Nurtec Odt Rimegepant Sulfate Brand 22 $29,569
Qulipta Atogepant Brand 26 $29,256
Nourianz Istradefylline Brand 13 $25,334
Aimovig Autoinjector Erenumab-Aooe Brand 31 $24,658
Ubrelvy Ubrogepant Brand 18 $21,207
Gabapentin Generic 215 $3,225
Memantine Hcl Generic 190 $2,575

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 43 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
  • Novartis Pharmaceuticals Corporation $403
$403 — —
Gocovri
  • US WorldMeds, LLC $350
$350 — —
Briviact
  • UCB, Inc. $282
$282 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $272
$272 22 —
NOURIANZ
  • Kyowa Kirin, Inc. $237
$237 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 43 with Patron

Records

368 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record